List view / Grid view
24 March 2006 | By EPR
Marc Casper, Senior Vice President, Thermo Electron Corp., believes there are exciting times ahead for R&D and that collaborations will speed the development of the tools required. Tim Lloyd found out more.
24 March 2006 | By Cees Gooijer, Freek Ariese and Reyer J. Dijkstra, Dept. of Analytical Chemistry and Applied Spectroscopy, Laser Centre Vrije Universiteit
Currently, Raman spectroscopy (RS) is rapidly becoming a mature analytical technique in the pharmaceutical world. Thus far, it is used almost exclusively in a stand-alone mode, since coupling with liquid separation methods hardly seemed realistic in practice. However, as outlined in this article, recent developments are quite promising and such…
24 March 2006 | By Dr. Manuela Scholz, Leiter der Herstellung (Product Supply Release Responsible), Procter & Gamble Pharmaceuticals
Due to the need for improvement in the cost structure and efficiency of the pharmaceutical industry, the introduction of NIR analytical techniques in combination with PAT applications is a promising opportunity for cycle time reduction and machine utilisation increase.
24 March 2006 | By E J MacLean, P J Rizkallah, CCLRC Daresbury Laboratory and J R Helliwell, School of Chemistry, The University of Manchester
Synchrotron radiation (SR) has had a profound impact on the capabilities of structural chemistry and biology. The first dedicated SR X-ray source was the UK’s SRS, which celebrated its 25th Anniversary in 2005. This article provides an overview and several case studies that illustrate the pivotal role that the pharmaceutical…
24 March 2006 | By Charles A. Lucy and Sarah Pelletier, Department of Chemistry, University of Alberta
Ion chromatography (IC) allows the determination of trace ions using low capacity high efficiency columns possessing fixed ion exchange sites. Combined with suppressed conductivity detection, IC yields parts-per-billion detection of the seven common inorganic anions (F-, Cl-, NO2-, Br-, NO3-, HPO42- and SO42-) and to a lesser extent carboxylic acids,…
24 March 2006 | By E. Allen, T. Mant, C. Vose: Guy’s Drug Research Unit, Quintiles Limited
Drug development has become more complex and significantly more expensive. There has been an estimated 55% increase in the critical path development costs since the year 20001. More than 50% of these costs are incurred in later phase development (Phase IIb and III studies).
24 March 2006 | By Bengt Ljungqvist, Ph.D. and Berit Reinmüller, Ph.D. KTH Stockholm
To verify that cleanroom and clean zones are adequately installed and functioning they are usually validated during three occupancy states. First, when the installation is complete with all services connected and functioning, as-built; secondly during at-rest conditions when equipment is installed and running in a manner agreed upon by customer…
2 February 2006 | By Quan Du, Institute of Molecular Medicine, Peking University, Meihong Chen, Chinese Human Genome Center Beijing, Claes Wahlestedt, Scripps Florida and Zicai Liang, Karolinska Institute
Although synthetic siRNA libraries are becoming more available, most high throughput siRNA library-based screening was carried out with siRNA libraries encoded by different vectors. In this article, siRNA library construction methods and HTS applications are summarised.
2 February 2006 | By Carmel B. Nanthakumar, Senior Research Scientist – Automated Imaging and Electrophysiology, Neuroscience Research Centre, Merck Sharp and Dohme
HCS has been implemented as a key technology to address complex biology associated with CNS drug targets. This review will describe a new generation of HCS assays including multiplexed HCS assays with biochemical markers, novel techniques for studying receptor internalisation and the application of HCS to neural network cultures that…
2 February 2006 | By Vahri Beaumont, Magnus Ivarsson and Keith A. Wafford, The Neuroscience Research Centre, Merck Sharp and Dohme, UK
In spite of an increased understanding of brain mechanisms in recent years, there has been a lack of major new drugs being registered for psychiatric and neurological conditions1,2. To prioritise drug discovery resources and provide early proof-of-concept studies for novel compounds and mechanisms, the pharmaceutical industry is increasingly focusing on…
2 February 2006 | By Kai A. Reidegeld, Michael Hamacher, Helmut E. Meyer, Christian Stephan; MPC, Medical Proteom-Center, Ruhr-University of Bochum, Martin Blüggel, Gerhard Körting, Daniel Chamrad, Christian Scheer; Protagen AG, Herbert Thiele; Bruker Daltonik GmbH, Chris Taylor, Michael Müller, Rolf Apweiler, Philip Jones; EBI, European Bioinformatics Institute, Lennart Martens; Department of Medical Protein Research, Ghent University
The proteome analysis started by the Human Proteome Organization (HUPO)1 is the second big international consortium project after the sequencing of the human genome by the Human Genome Project (HUGO)2. The aim of the HUPO Brain Proteome Project (BPP)3 is to derive in depth knowledge of the brain from analysing…
2 February 2006 | By Professor David Littlejohn, Head of the Department of Pure and Applied Chemistry at the University of Strathclyde, Director of CPACT at the University of Strathclyde
There can be no doubt that the FDA’s initiative on Process Analytical Technologies (PAT) has had an enormous impact on the pharmaceutical industries. However, the emergence of ’born again‘ PAT devotees in pharma companies has caused mild amusement in other industries where on-line analysis has been an integral part of…
2 February 2006 | By Elisabeth Pook, Stefan Martin Mundt, Adrian Tersteegen, Department of Cardiovascular Research, Pharma Research Center Wuppertal, Bayer HealthCare AG
Ultra high-throughput screening (UHTS) offers the possibility to discover novel pharmacophores. To benefit from UHTS special demands concerning assay quality and data analysis have to be met.
2 February 2006 | By Jacques Hamon, Kamal Azzaoui, Steven Whitebread, Laszlo Urban, Edgar Jacoby, Bernard Faller, Novartis Institutes for BioMedical Research
One major cause of the late failure of drugs in development (i.e. attrition) is the lack of clinical safety of the compounds (accounting for approximately 30% of failures together with toxicology)1. One of the key elements is the off-target effects of the compounds, causing adverse drug reaction (ADRs).
2 February 2006 | By Anthony M. Cundell, Ph.D. Consulting Microbiologist
Since the 2000 publication of the PDA Technical Report Number 33 Testing Methods, rapid microbial methods (RMM) have not lived up to their promise for changing routine Quality Control microbiological testing in the pharmaceutical industry. With the next generation of rapid microbial methods emerging from the R&D laboratories of instrument…
